A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease
A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease
复制标题
DOI：
10.1191/1358863x05vm637oa
复制
发表时间：
2005-01-01
影响因子：
3.5
通讯作者：
Cooke, JP
中科院分区：
文献类型：
--
作者：
Oka, RK;Szuba, A;Cooke, JP
外周动脉疾病（PAD）损害行走能力，通常伴有严重的内皮血管舒张功能障碍，其特征是生物活性和/或内皮源性一氧化氮（NO）合成降低。先前的研究表明，膳食补充l -精氨酸（一氧化氮的前体）可以改善内皮依赖性血管舒张，四肢血流量和步行距离。然而，这些研究都是小规模的，并且使用了大剂量的l -精氨酸静脉注射。l -精氨酸的最佳剂量尚未确定。因此，本初步研究旨在确定l -精氨酸的最低有效口服剂量，以改善步行距离，为最终研究做准备。伴有PAD和间歇性跛行的患者（n = 80）参与了这项研究。入选标准包括：(1)休息时踝臂指数(ABI) = 25%；的绝对跛行距离差
Peripheral arterial disease (PAD) impairs walking capacity and is often associated with a profound endothelial vasodilator dysfunction, characterized by reduced bioactivity and/or synthesis of endothelium-derived nitric oxide (NO). Previous studies have suggested that dietary supplementation Of L-arginine, the precursor of NO, improves endothelium-dependent vasodilation, limb blood flow and walking distance. However, these studies have been small, and have used large intravenous doses Of L-arginine. The optimal dose Of L-arginine has not been determined. Accordingly, this pilot study was conducted to establish the lowest effective oral dose Of L-arginine to improve walking distance in preparation for the definitive study. Patients with PAD and intermittent claudication (n = 80) participated in this study. Eligibility criteria included: (1) ankle-brachial index (ABI) at rest = 25%; and (3) difference in absolute claudication distance of